Your browser doesn't support javascript.
loading
Biologic Agents for the Treatment of Hypereosinophilic Syndromes.
Kuang, Fei Li; Klion, Amy D.
Afiliação
  • Kuang FL; Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Md.
  • Klion AD; Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Md. Electronic address: aklion@nih.gov.
J Allergy Clin Immunol Pract ; 5(6): 1502-1509, 2017.
Article em En | MEDLINE | ID: mdl-29122152
Hypereosinophilic syndromes (HES) are a heterogeneous group of rare disorders defined by the presence of marked peripheral or tissue eosinophilia resulting in end-organ damage. Although conventional therapies, including glucocorticoids, hydroxyurea, and IFN-α, are initially effective in reducing eosinophilia and symptoms in a majority of patients with platelet-derived growth factor mutation-negative HES, the development of resistance and treatment-related toxicity are common. In contrast, targeted therapy with the tyrosine kinase inhibitor, imatinib, is well tolerated but effective only in the subset of patients with HES with a primary myeloid disorder. Eosinophil-targeted biotherapeutics offer the potential of improved efficacy with few, if any, adverse effects. The aims of this review are to provide an overview of current approaches to the use of conventional HES therapies and a discussion of existing biotherapeutics that target eosinophils and their potential use in the treatment of HES. With the continuing expansion of eosinophil-targeted biotherapeutics, the future for patients with eosinophilic disorders is promising.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores Biológicos / Síndrome Hipereosinofílica Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores Biológicos / Síndrome Hipereosinofílica Limite: Humans Idioma: En Revista: J Allergy Clin Immunol Pract Ano de publicação: 2017 Tipo de documento: Article País de publicação: Estados Unidos